Physician profile
Todd Broome
NPI 1588636757
$7,109.51
in general payments reported to CMS, 2019-2025
31 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $1,592 · 2021: $465 · 2022: $1,015 · 2023: $950 · 2024: $1,041 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,446.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,237.01 | 2020-2024 | Pristine |
| Vifor Pharma, INC. | $666.76 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $592.78 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $492.63 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $485.22 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $478.74 | 2024-2025 | |
| Glaxosmithkline, LLC. | $456.24 | 2020-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $368.56 | 2021-2024 | |
| Travere Therapeutics, INC. | $353.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.18 | 2024-2025 | Jardiance |
| Amgen INC. | $206.49 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Fresenius USA Marketing, INC. | $190.24 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $157.78 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $148.43 | 2022-2025 | Lupkynis |
| Novo Nordisk INC | $133.69 | 2022-2025 | Ozempic, Rybelsus |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $116.09 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $98.92 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $89.41 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $81.76 | 2020-2023 | Soliris |
| Ultragenyx Pharmaceutical INC. | $74.35 | 2021-2023 | |
| Medtronic, INC. | $73.99 | 2021-2025 | Symplicity G3 |
| Horizon Therapeutics Plc | $66.20 | 2019-2023 | Krystexxa |
| Cycle Pharmaceuticals INC | $59.89 | 2025 | Venxxiva |
| Takeda Pharmaceuticals U.S.A., INC. | $42.37 | 2020-2021 | |
| Akebia Therapeutics INC | $40.57 | 2020-2023 | Auryxia |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.94 | 2025 | |
| Mallinckrodt Hospital Products INC. | $18.17 | 2020 | |
| Cormedix INC. | $18.10 | 2024 | Defencath |
| Genentech USA, INC. | $15.73 | 2019 | |
| Kyowa Kirin, INC. | $15.08 | 2023 | Crysvita |
| Lemaitre Vascular, INC. | $13.52 | 2025 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Broome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.